Combination therapy including a KRAS G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
Grant
US12582657B2
Kind: B2
Mar 24, 2026
Assignee
Amgen Inc.
Inventors
James Russell Lipford, Jude Robert Canon, Anne Y. Saiki, Karen Louise Rex
Abstract
The present invention provides combination therapy that includes an KRASG12C inhibitor, such as or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
CPC Classifications
A61P 35/00
A61K 45/06
A61K 31/519
A61K 31/506
A61K 31/555
A61K 39/3955
A61K 2300/00
C07K 16/2818
Filing Date
2023-12-19
Application No.
18545953
Claims
30